Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2001

View Archived Issues

AlphaGene and Lahey Clinic form strategic alliance for prostate cancer research

Celltech and NeoGenesis form research collaboration

AtheroGenics acquires new drug discovery technology

FDA approves study of vagus nerve stimulation for migraine

Clinical study of VNS for rapid cycling bipolar disorder cleared by U.S. authorities

Once-daily dosing of RWJ-270201 appears feasible according to pharmacodynamic analysis

KB-R7785, a new MMP inhibitor, reduces brain damage in focal cerebral ischemia

Glimepiride may be safer than conventional sulfonylureas in diabetics with coronary artery disease

Weston Medical regains European rights to Intraject; Abbott license agreement reported

Novel pharmacological effect described for tyrosine kinase inhibitor STI-571

Genzyme General continues to make good progress in advancing development programs

Merck completes acquisition of Rosetta

Salmosin gene therapy associated with antitumor and antimetastatic effects in mouse model

FDA approves changes in Copaxone labeling

Pfizer achieves important milestones during Q2 2001

Adenovirus-mediated CTLA4IgG gene therapy prevents development of arthritis

Texas Biotechnology receives approvable letter from FDA for expanded argatroban indication

Bisphosphonates recommended as first-line therapy for GIO

Pharmos provides update on key products

Red blood cell-mediated delivery of an antiviral prodrug useful against HIV and HSV

Inhibitors of Ras farnesylation and use in hyperproliferative diseases

Bradykinin antagonists, pharmaceutical compositions and methods of use

MethylGene designs histone deacetylase inhibitors useful for cancer, restenosis, psoriasis

Preparation and use of new potassium channel inhibitors described by BMS

Fujisawa claims new series of adenosine receptor antagonists

Research at U.S. university leads to new cell regulation modulators

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....